Ekaphop Sirachainan

977 total citations
37 papers, 432 citations indexed

About

Ekaphop Sirachainan is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ekaphop Sirachainan has authored 37 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 14 papers in Surgery and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ekaphop Sirachainan's work include Lung Cancer Treatments and Mutations (8 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). Ekaphop Sirachainan is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). Ekaphop Sirachainan collaborates with scholars based in Thailand, China and United States. Ekaphop Sirachainan's co-authors include Noppadol Larbcharoensub, T. Sirisinha, Nuttapong Ngamphaiboon, Poompis Pattaranutaporn, V. Ratanatharathorn, Monpat Chamnanphon, Chonlaphat Sukasem, Tavan Janvilisri, Touch Ativitavas and Ravat Panvichian and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Ekaphop Sirachainan

37 papers receiving 424 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ekaphop Sirachainan Thailand 12 264 88 84 81 80 37 432
Daniel R. Carrizosa United States 11 191 0.7× 30 0.3× 68 0.8× 33 0.4× 112 1.4× 41 440
Sayed Ali Australia 13 307 1.2× 38 0.4× 188 2.2× 33 0.4× 134 1.7× 25 530
Kylea Potvin Canada 10 154 0.6× 47 0.5× 120 1.4× 52 0.6× 65 0.8× 28 341
Bas Peters Netherlands 15 167 0.6× 142 1.6× 94 1.1× 57 0.7× 149 1.9× 38 464
Carina Pereira Portugal 13 115 0.4× 106 1.2× 163 1.9× 14 0.2× 63 0.8× 31 453
Brendell Williams United States 4 180 0.7× 63 0.7× 139 1.7× 5 0.1× 134 1.7× 4 447
Xin Cai China 14 288 1.1× 177 2.0× 120 1.4× 7 0.1× 103 1.3× 39 638
Myla Lai-Goldman United States 10 255 1.0× 69 0.8× 146 1.7× 30 0.4× 94 1.2× 14 473

Countries citing papers authored by Ekaphop Sirachainan

Since Specialization
Citations

This map shows the geographic impact of Ekaphop Sirachainan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ekaphop Sirachainan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ekaphop Sirachainan more than expected).

Fields of papers citing papers by Ekaphop Sirachainan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ekaphop Sirachainan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ekaphop Sirachainan. The network helps show where Ekaphop Sirachainan may publish in the future.

Co-authorship network of co-authors of Ekaphop Sirachainan

This figure shows the co-authorship network connecting the top 25 collaborators of Ekaphop Sirachainan. A scholar is included among the top collaborators of Ekaphop Sirachainan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ekaphop Sirachainan. Ekaphop Sirachainan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Muntham, Dittapol, Pimpin Incharoen, Touch Ativitavas, et al.. (2024). Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer. BMC Cancer. 24(1). 200–200. 5 indexed citations
2.
He, Aiwu Ruth, Benjamin Tan, Thatthan Suksombooncharoen, et al.. (2023). Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study.. Journal of Clinical Oncology. 41(4_suppl). 550–550. 2 indexed citations
3.
Sirachainan, Ekaphop, et al.. (2023). Healthcare coverage affects survival of EGFR-mutant Thai lung cancer patients. Frontiers in Oncology. 13. 1047644–1047644. 1 indexed citations
4.
Tanasanvimon, Suebpong, Krittiya Korphaisarn, Jitlada Juengsamarn, et al.. (2022). MO5-3 Efficacy and patient-report outcomes of atezolizumab/ bevacizumab for unresectable hepatocellular carcinoma in Thailand. Annals of Oncology. 33. S484–S484. 1 indexed citations
5.
Chansriwong, Phichai, Ekaphop Sirachainan, Thanyanan Reungwetwattana, et al.. (2020). Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Scientific Reports. 10(1). 13486–13486. 28 indexed citations
6.
7.
Sirachainan, Ekaphop, et al.. (2017). Prognostic factors of survival outcomes in colorectal cancer patients with liver metastasis. Annals of Oncology. 28. iii106–iii107. 1 indexed citations
8.
Sirachainan, Ekaphop, et al.. (2017). Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population. OncoTargets and Therapy. Volume 10. 4955–4968. 5 indexed citations
9.
Tulalamba, Warut, et al.. (2015). Transcriptome meta-analysis reveals dysregulated pathways in nasopharyngeal carcinoma. Tumor Biology. 36(8). 5931–5942. 9 indexed citations
10.
Ngamphaiboon, Nuttapong, et al.. (2014). A phase II randomized, double-blind placebo-controlled trial of an antiemetic, 6-gingerol in solid tumor patients receiving moderately to highly emetogenic adjuvant chemotherapy.. Journal of Clinical Oncology. 32(15_suppl). 9647–9647. 2 indexed citations
11.
Larbcharoensub, Noppadol, et al.. (2014). Esthesioneuroblastoma metastasis to the breast: A case report and review of the literature. Oncology Letters. 8(4). 1505–1508. 4 indexed citations
12.
Lopes, Gilberto, Jeonghoon Ahn, Min Hu, et al.. (2013). Roles of Cancer Registries in Enhancing Oncology Drug Access in the Asia-Pacific Region. Asian Pacific Journal of Cancer Prevention. 14(4). 2159–2165. 2 indexed citations
13.
Butthongkomvong, Kritiya, et al.. (2013). Treatment Outcome of Palliative Chemotherapy in Inoperable Cholangiocarcinoma in Thailand. Asian Pacific Journal of Cancer Prevention. 14(6). 3565–3568. 21 indexed citations
14.
Sirachainan, Ekaphop, Monpat Chamnanphon, T. Sirisinha, et al.. (2012). Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand. Asian Pacific Journal of Cancer Prevention. 13(9). 4549–4553. 35 indexed citations
15.
Sirachainan, Ekaphop, et al.. (2012). CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. SHILAP Revista de lepidopterología. 5. 149–149. 27 indexed citations
16.
17.
Sirisinha, T., et al.. (2006). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation Study of the Thai Version. Quality of Life Research. 15(1). 167–172. 43 indexed citations
18.
Ratanatharathorn, V., et al.. (2000). Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.. PubMed. 83(10). 1187–95. 2 indexed citations
19.
Sirachainan, Ekaphop, et al.. (2000). Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): a preliminary report.. PubMed. 83(1). 85–92. 5 indexed citations
20.
Ratanatharathorn, V., et al.. (1998). Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): a preliminary study.. PubMed. 81(10). 763–71. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel R. Carrizosa Breakdown of academic impact, for papers by Sayed Ali Breakdown of academic impact, for papers by Kylea Potvin Breakdown of academic impact, for papers by Bas Peters Breakdown of academic impact, for papers by Carina Pereira Breakdown of academic impact, for papers by Brendell Williams Breakdown of academic impact, for papers by Xin Cai Breakdown of academic impact, for papers by Myla Lai-Goldman
Rankless by CCL
2026